Nucleic acid composition for mRNA delivery and expression and application thereof
By designing nucleic acid compositions with nucleic acid compositions I and II modified by membrane-penetrating peptides, mRNA is combined to form nanostructures, solving the problem of insufficient mRNA delivery efficiency and stability in the prior art, and achieving efficient expression in cells and Simplify operations.
Patent Information
- Application Number
- CN202411198492.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-08-29
AI Technical Summary
Existing mRNA delivery methods require a large number of auxiliary substances, which are complex in operation and difficult to guarantee uniformity, resulting in insufficient efficiency and stability of mRNA delivery in cells.
Design a nucleic acid composition to form a nano-sized nucleic acid composition by complementary binding of mRNA with nucleic acid composition I and nucleic acid composition II, and use membrane-penetrating peptide modification to improve the delivery efficiency of mRNA and ensure efficient expression of mRNA in cells. .
It realizes efficient delivery and expression of mRNA in cells, reduces interference in binding intervals, improves delivery efficiency and stability, and simplifies the operation process.
Smart Images

Figure CN119074938A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and in particular to a nucleic acid composition for mRNA delivery and expression and an application thereof. Background Art
[0002] In recent years, mRNA has become a forward-looking strategy for the treatment of various diseases as a substitute for protein drugs. However, mRNA in its natural state faces many obstacles such as electrostatic repulsion and nuclease degradation when entering cells without the assistance of a carrier. Solving the above problems is the core solution to promote the application of mRNA. Nanoformulations can use their unique delivery methods to interact with cells with drugs, proteins or nucleic acid molecules, and achieve controlled release. It is also the main way to solve the problems of mRNA intracellular delivery efficiency and stability. Specifically, common schemes include encapsulating mRNA into nano-sized carriers (such as lipo8000, LNP, etc.), loading mRNA onto nanomaterials, and nano-sizing mRNA with metal ions.
[0003] The above mRNA delivery methods usually require auxiliary substances that are much larger than the mass of the mRNA itself for construction, and there are also problems such as complex operation and difficulty in ensuring uniformity. Here, the present invention hopes to develop a simplified operation strategy to achieve efficient delivery and expression of mRNA to cultured cells and living cells. Summary of the invention
[0004] The purpose of the present invention is to provide a nucleic acid composition for mRNA delivery and expression and its application to solve the problems existing in the above-mentioned prior art. The nucleic acid composition can achieve efficient delivery and expression of mRNA in cells.
[0005] To achieve the above object, the present invention provides the following solutions:
[0006] The present invention provides a nucleic acid composition for mRNA delivery and expression, wherein the nucleic acid composition comprises mRNA, a nucleic acid composition I and a nucleic acid composition II; the nucleic acid composition I and the nucleic acid composition II are complementary to the mRNA;
[0007] The mRNA is divided into N mRNA结合区 mRNA binding region and N mRNA结合区 -1 mRNA active region; the mRNA binding region and the mRNA active region are alternately distributed in sequence; the N mRNA结合区 The mRNA binding regions are numbered from binding region 1 to binding region N. mRNA结合区 ; The length L of the mRNA binding region mRNA结合区 is 5-20nt; the length L of the mRNA active region mRNA活性区 10-150 nt;
[0008] The length of mRNA L mRNA =L mRNA结合区 ×N mRNA结合区 +L mRNA活性区 ×(N mRNA结合区 -1);
[0009] The nucleic acid sequence I is divided into N 核酸组合物I结合区 A nucleic acid composition I binding region and N 核酸组合物I间隔区 The nucleic acid composition I spacer region; the nucleic acid composition I binding region and the nucleic acid composition I spacer region are alternately distributed in sequence; and are numbered as nucleic acid composition I binding region 1 to nucleic acid composition I binding region N in sequence. 核酸组合物I结合区 ;
[0010] The length of the spacer region of the nucleic acid composition I is 1-10 nt;
[0011] N 核酸组合物I结合区 =N 核酸组合物I间隔区 ;
[0012] The nucleic acid sequence II is divided into N 核酸组合物II结合区 Nucleic acid composition II binding region and N 核酸组合物II间隔区 The nucleic acid composition II spacer region; the nucleic acid composition II binding region and the nucleic acid composition II spacer region are alternately distributed in sequence; the N 核酸组合物II结合区 The nucleic acid composition II binding regions are numbered sequentially as nucleic acid composition II binding region 1 to nucleic acid composition II binding region N. 核酸组合物II结合区 ;
[0013] The length of the spacer region of the nucleic acid composition II is 1-10 nt;
[0014] N 核酸组合物II结合区 =N 核酸组合物II间隔区 ;
[0015] N 核酸组合物I结合区 +N 核酸组合物II结合区 =N mRNA结合区 ;
[0016] The nucleic acid composition I binding region 1 to the nucleic acid composition I binding region N 核酸组合物I结合区 The nucleic acid composition II binding region 1 to the nucleic acid composition II binding region N are complementary to the odd-numbered mRNA binding regions in sequence; 核酸组合物II结合区 They are complementary to the even-numbered mRNA binding regions in sequence.
[0017] Furthermore, both the nucleic acid composition I and the nucleic acid composition II are modified with a cell-penetrating peptide.
[0018] Furthermore, the cell-penetrating peptide is TAT.
[0019] Furthermore, the nucleic acid sequence I is circular DNA, circular RNA, single-stranded DNA or single-stranded RNA; the nucleic acid sequence II is circular DNA, circular RNA, single-stranded DNA or single-stranded RNA.
[0020] Furthermore, the nucleotide sequence of the spacer region of the nucleic acid composition I is CCCCCC; the nucleotide sequence of the spacer region of the nucleic acid composition II is CCCCCC.
[0021] The present invention also provides a method for improving the delivery efficiency of mRNA, comprising the steps of complementary binding of nucleic acid composition I and nucleic acid composition II to the mRNA to form a nucleic acid composition, so as to improve the delivery efficiency of the mRNA;
[0022] The mRNA is divided into N mRNA结合区 mRNA binding region and N mRNA结合区 -1 mRNA active region; the mRNA binding region and the mRNA active region are alternately distributed in sequence; the N mRNA结合区 The mRNA binding regions are numbered from binding region 1 to binding region N. mRNA结合区 ; The length L of the mRNA binding region mRNA结合区 is 5-20nt; the length L of the mRNA active region mRNA活性区 10-150 nt;
[0023] The length of mRNA L mRNA =L mRNA结合区 ×N mRNA结合区 +L mRNA活性区 ×(N mRNA结合区 -1);
[0024] The nucleic acid sequence I is divided into N 核酸组合物I结合区 A nucleic acid composition I binding region and N 核酸组合物I间隔区 The nucleic acid composition I spacer region; the nucleic acid composition I binding region and the nucleic acid composition I spacer region are alternately distributed in sequence; and are numbered as nucleic acid composition I binding region 1 to nucleic acid composition I binding region N in sequence. 核酸组合物I结合区 ;
[0025] The length of the spacer region of the nucleic acid composition I is 1-10 nt;
[0026] N 核酸组合物I结合区 =N 核酸组合物I间隔区 ;
[0027] The nucleic acid sequence II is divided into N 核酸组合物II结合区 Nucleic acid composition II binding region and N 核酸组合物II间隔区 The nucleic acid composition II spacer region; the nucleic acid composition II binding region and the nucleic acid composition II spacer region are alternately distributed in sequence; the N 核酸组合物II结合区The nucleic acid composition II binding regions are numbered sequentially as nucleic acid composition II binding region 1 to nucleic acid composition II binding region N. 核酸组合物II结合区 ;
[0028] The length of the spacer region of the nucleic acid composition II is 1-10 nt;
[0029] N 核酸组合物II结合区 =N 核酸组合物II间隔区 ;
[0030] N 核酸组合物I结合区 +N 核酸组合物II结合区 =N mRNA结合区 ;
[0031] The nucleic acid composition I binding region 1 to the nucleic acid composition I binding region N 核酸组合物I结合区 The nucleic acid composition II binding region 1 to the nucleic acid composition II binding region N are complementary to the odd-numbered mRNA binding regions in sequence; 核酸组合物II结合区 They are complementary to the even-numbered mRNA binding regions in sequence.
[0032] Furthermore, both the nucleic acid composition I and the nucleic acid composition II are modified with a cell-penetrating peptide.
[0033] Furthermore, the method for modifying the cell-penetrating peptide with the nucleic acid composition I comprises: performing azide modification on the nucleic acid sequence I to obtain an azide-functionalized nucleic acid composition I, and then reacting with a DBCO-modified cell-penetrating peptide to obtain a cell-penetrating peptide-modified nucleic acid composition I;
[0034] The method for modifying the cell-penetrating peptide with the nucleic acid composition II comprises: performing azide modification on the nucleic acid sequence II to obtain an azide-functionalized nucleic acid composition II, and then reacting with a DBCO-modified cell-penetrating peptide to obtain a cell-penetrating peptide-modified nucleic acid composition II.
[0035] Furthermore, the nucleotide sequence of the spacer region of the nucleic acid composition I is CCCCCC; the nucleotide sequence of the spacer region of the nucleic acid composition II is CCCCCC.
[0036] The present invention also provides the use of the above-mentioned nucleic acid composition for mRNA delivery and expression in the preparation of mRNA drugs.
[0037] The present invention discloses the following technical effects:
[0038] The present invention provides a nucleic acid composition for mRNA delivery and expression. Compared with the prior art, the beneficial effect of the present invention is that the present invention complementarily combines mRNA with nucleic acid composition I and nucleic acid composition II to form a nucleic acid composition with uniform physical characteristics, wherein nucleic acid composition I and nucleic acid composition II contain multiple mRNA binding regions, which can be accurately paired with corresponding regions on mRNA; there are spacers between each binding region to reduce interference between each binding region. After co-incubation of mRNA with nucleic acid composition I and nucleic acid composition II, they can form a nano-sized nucleic acid composition. In the nucleic acid composition, mRNA is connected by nucleic acid composition I and nucleic acid composition II in a preset manner, and the nucleic acid composition after connection still contains a large amount of mRNA active region exposure, which is conducive to efficient delivery and expression of mRNA in cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0040] Figure 1 is a schematic diagram of the structure of a nucleic acid composition;
[0041] Figure 2 An atomic force microscopy characterization image of a nucleic acid composition;
[0042] Figure 3 The detection results of the delivery and expression of the nucleic acid composition into artificial cultured cells;
[0043] Figure 4 The detection results of the delivery and expression of the nucleic acid composition into living cells;
[0044] Figure 5 The results are the test results of delivery and expression of nucleic acid compositions without cell-penetrating peptide modification to in vitro cultured cells and living cells. DETAILED DESCRIPTION
[0045] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0046] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.
[0047] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.
[0048] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.
[0049] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.
[0050] The present invention provides a nucleic acid composition for intracellular delivery and expression of mRNA. With mRNA as the core skeleton, the mRNA is connected with the help of nucleic acid composition I and nucleic acid composition II to form a nano-sized nucleic acid composition, which is specifically manifested in that nucleic acid composition I and nucleic acid composition II contain multiple mRNA binding regions, which can be accurately paired and combined with corresponding regions on mRNA; the mRNA in the nucleic acid composition is connected by nucleic acid composition I and nucleic acid composition II in a preset manner, and the nucleic acid composition after connection still contains a large number of mRNA active regions exposed, so as to facilitate the intracellular delivery of the nucleic acid composition and the expression of mRNA in cells ( Figure 1 ). Except for the capping region at the 5' end and the poly A tail region at the 3' end, the mRNA has functional regions (i.e., exons) in the middle, which can be further translated into proteins in the cell. The functional regions of mRNA are divided into binding regions and active regions according to the binding characteristics of the nucleic acid composition, wherein the binding region binds to the corresponding nucleic acid composition I and nucleic acid composition II. The present invention limits the length of the binding region (L mRNA结合区 ) and active zone length (L mRNA活性区 ), therefore, the number of binding regions (NmRNA结合区 ) and the number of active areas (N mRNA活性区 ) will vary with the length of mRNA (L mRNA , excluding the 5' end capping region and the 3' end poly A tail region). Nucleic acid composition I and nucleic acid composition II also include two characteristic regions: a binding region and a spacer region. The present invention limits the length of the binding region (L 结合区 ) and the length of the spacer (L 间隔区 ), therefore, the number of binding regions (N 核酸组合物I结合区 、N 核酸组合物II结合区 ) and the number of spacers (N 核酸组合物I间隔区 、N 核酸组合物II间隔区 ) will also vary with the length of the mRNA. Based on the fact that the nucleic acid composition is a symmetrical model, the design rules are as follows:
[0051] i mRNA结合区 ×N mRNA结合区 +L mRNA活性区 ×N mRNA活性区 =L mRNA ;
[0052] ii.N mRNA结合区 =N mRNA活性区 +1;
[0053] iii.N 核酸组合物I结合区 +N 核酸组合物II结合区 =N mRNA结合区 ;
[0054] iv.N 核酸组合物I间隔区 =N 核酸组合物I结合区 ;
[0055] v 核酸组合物II间隔区 =N 核酸组合物II结合区 ;
[0056] vi.N=int[N];
[0057] Among them, N represents the number; L represents the length; int[] is the floor function.
[0058] The method of the present invention is described below by taking the tool mRNA, mcherry mRNA (translated into red fluorescent protein, 861 nt in length), as an example.
[0059] Example 1 Construction and characterization of nucleic acid compositions
[0060] The 5' end of mcherry mRNA contains Cap1AG capping, N1-me-pseudoU modified bases in the middle (to reduce immunogenicity), and a polyA tail at the 3' end. The length of the active region is set to 90nt, the length of the binding region is set to 17nt, and the number of binding regions is calculated to be 5. The feasibility of constructing the nucleic acid composition was observed by modifying the nucleic acid composition I and the nucleic acid composition II to bind the transmembrane peptide (TAT), and then binding to the mRNA. The following steps are included:
[0061] Step a: Nucleic acid sequence I or II is modified with a cell-penetrating peptide TAT. The cell-penetrating peptide is coupled to the nucleic acid sequence I or II using a click chemistry reaction, and the specific operation is as follows: in a total volume of 100 μL buffer, the nucleic acid sequence I (SEQ ID NO.1 in Table 1) and the nucleic acid sequence II (SEQ ID NO.2 in Table 1) are respectively mixed with NHS-PEG4-N3 cross-linker at a molar ratio of 30 μM:1.5 mM, and magnetically stirred for 2 h (1000 rpm) at room temperature, and purified by ultrafiltration and centrifugation to obtain azide-modified nucleic acid composition I and azide-modified nucleic acid composition II; the azide-modified nucleic acid composition I and the azide-modified nucleic acid composition II are respectively incubated with DBCO-modified cell-penetrating peptide (TAT) at a molar ratio of 10 μM:100 μM at 4°C for 1 day, and magnetically stirred (1000 rpm) and ultrafiltration and centrifugation are performed to obtain cell-penetrating peptide-modified nucleic acid composition I and cell-penetrating peptide-modified nucleic acid composition II.
[0062] Table 1 Nucleotide sequences
[0063]
[0064]
[0065] Note: Nucleic acid sequence I and nucleic acid sequence II are both circular RNAs connected end to end; the underlined region indicates the spacer region.
[0066] Step b: mcherry mRNA, cell-penetrating peptide-modified nucleic acid composition I and cell-penetrating peptide-modified nucleic acid composition II were mixed in a 1×TAE / Mg solution at a molar ratio of 1:1:1. 2+ The mixture was mixed in a buffer solution, reacted at 65°C for 10 minutes, and cooled to room temperature within 2 hours to obtain a nucleic acid composition containing mRNA. The morphology was characterized by atomic force microscopy. The results are as follows Figure 2 shown. Figure 2 The control group in the middle shows the morphological characterization results of nucleic acid sequence I and nucleic acid sequence II mixed in a molar ratio of 1:1.
[0067] from Figure 2It can be seen that the cell-penetrating peptide-modified nucleic acid composition I / II shows a uniform dot-like appearance under an atomic force microscope. At the same time, after the two react, the nucleic acid composition containing mRNA shows a nano-like morphology, indicating that the nucleic acid composition is successfully constructed, which is conducive to subsequent verification at the cell level.
[0068] Example 2 Characterization of the effect of nucleic acid composition on assisting mRNA delivery to in vitro cultured cells and living cells
[0069] In vitro cell experiments:
[0070] 1×10 4 HeLa cells were seeded in a confocal culture dish and incubated at 37°C for 24 hours. Three groups were set up respectively: blank control, mRNA (mcherry mRNA) and a nucleic acid composition containing mRNA (prepared in Example 1). The mRNA and mRNA-containing nucleic acid composition groups were incubated with mcherry mRNA or a nucleic acid composition containing mRNA and cells under the same conditions (mRNA concentration, incubation time and buffer). After 2 hours, Hoechst was added to stain the live cell nuclei for locating the cells. The blank control group was incubated directly with cells without adding mcherry mRNA or a nucleic acid composition containing mRNA. After 2 hours, Hoechst was added to stain the live cell nuclei for locating the cells. The above-mentioned groups of cells were photographed confocally, and filters (ex: 587nm, em: 610nm) were used to image mcherry mRNA, and filters (ex: 350nm, em: 460nm) were used to image Hoechst dye, so as to obtain the intracellular fluorescence intensity and perform comparative analysis. The results are shown as follows: Figure 3 shown.
[0071] Tissue (living cell) experiments:
[0072] The mRNA or nucleic acid composition was injected into the subcutaneous tumor (MCF-7 breast cancer) of nude mice. Three groups were also set: blank control, mRNA (mcherry mRNA) and nucleic acid composition containing mRNA (prepared in Example 1). The mRNA and nucleic acid composition containing mRNA groups were injected with mcherry mRNA or nucleic acid composition containing mRNA under the same conditions (mRNA concentration, incubation time, buffer), and then the tumor tissue was taken out to make tissue slices. The blank control was injected with an equal amount of PBS. The tumor slices of the above groups were photographed by confocal microscopy, and the mcherry mRNA was imaged using a filter (ex: 587nm, em: 610nm), and the DAPI dye was imaged using a filter (ex: 350nm, em: 460nm), so as to obtain the intracellular fluorescence intensity and perform comparative analysis. The results are shown as follows: Figure 4 shown.
[0073] from Figure 3 It can be seen that when mRNA is incubated with cells alone, it is almost difficult to enter the cells and the fluorescence is weak; however, when it forms a nucleic acid composite, it can be delivered into the cells due to the special characteristics of its nanostructure and exhibits fluorescence. Figure 4 It can be seen that under the same conditions, the mcherry mRNA forming the nucleic acid composition can still be expressed in tissues (living cells) and exhibit fluorescence, which means that the nucleic acid composition can effectively deliver mRNA into living cells and achieve intracellular expression.
[0074] Example 3
[0075] Method for constructing nucleic acid composition:
[0076] mcherry mRNA, nucleic acid sequence I (SEQ ID NO.1) and nucleic acid sequence II (SEQ ID NO.2) were mixed in a 1×TAE / MgCl2 medium at a molar ratio of 1:1:1. 2+ The mixture was mixed in a buffer solution, reacted at 65° C. for 10 min, and cooled to room temperature within 2 h to obtain a nucleic acid composition containing mRNA.
[0077] Example 4 Characterization of the effect of nucleic acid composition without cell-penetrating peptide modification on mRNA delivery to in vitro cultured cells and living cells
[0078] In vitro cell experiments:
[0079] 1×10 4 HeLa cells were seeded in a confocal culture dish and incubated at 37°C for 24 hours. Two groups were set up: a blank control and a nucleic acid composition group containing mRNA. The nucleic acid composition group containing mRNA was incubated with the mRNA-containing nucleic acid composition prepared in Example 3 under the same conditions as in Example 2. Hoechst was added 2 hours later to stain the live cell nuclei for locating the cells. The blank control group was incubated directly with the cells without adding the nucleic acid composition containing mRNA. Hoechst was added 2 hours later to stain the live cell nuclei for locating the cells. The above-mentioned groups of cells were photographed confocally, and filters (ex: 587nm, em: 610nm) were used to image mcherry mRNA, and filters (ex: 350nm, em: 460nm) were used to image Hoechst dye, so as to obtain the intracellular fluorescence intensity and perform comparative analysis. The results are as follows: Figure 5 shown.
[0080] Tissue (living cell) experiments:
[0081] The nucleic acid composition was injected into the subcutaneous tumor (MCF-7 breast cancer) of nude mice. Two groups were also set up: a blank control and a nucleic acid composition group containing mRNA. Under the same conditions as in Example 2, the nucleic acid composition group containing mRNA was injected with the mRNA-containing nucleic acid composition prepared in Example 3, and then the tumor tissue was taken out to make tissue slices. The blank control was injected with an equal amount of PBS. The tumor slices of the above groups were photographed confocally, and the mcherry mRNA was imaged using a filter (ex: 587nm, em: 610nm), and the DAPI dye was imaged using a filter (ex: 350nm, em: 460nm), so as to obtain the intracellular fluorescence intensity and perform comparative analysis. The results are shown as follows: Figure 5 shown.
[0082] from Figure 5 It can be seen that the nucleic acid composition without membrane-penetrating peptide modification can still maintain its performance, deliver mRNA into cells and tissues (living cells) based on the particularity of its nanostructure, and exhibit fluorescence.
[0083] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.
Claims
1. A nucleic acid composition for mRNA delivery and expression, characterized in that: The nucleic acid composition comprises mRNA, nucleic acid composition I and nucleic acid composition II; the nucleic acid composition I and the nucleic acid composition II are complementary to the mRNA; The mRNA is divided into N mRNA结合区 mRNA binding region and N mRNA结合区 -1 mRNA active region; the mRNA binding region and the mRNA active region are alternately distributed in sequence; the N mRNA结合区 The mRNA binding regions are numbered from binding region 1 to binding region N. mRNA结合区 ; The length L of the mRNA binding region mRNA结合区 is 5-20nt; the length L of the mRNA active region mRNA活性区 10-150 nt; The length of mRNA L mRNA =L mRNA结合区 ×N mRNA结合区 +L mRNA活性区 ×(N mRNA结合区 -1); The nucleic acid sequence I is divided into N 核酸组合物I结合区 A nucleic acid composition I binding region and N 核酸组合物I间隔区 The nucleic acid composition I spacer region; the nucleic acid composition I binding region and the nucleic acid composition I spacer region are alternately distributed in sequence; and are numbered as nucleic acid composition I binding region 1 to nucleic acid composition I binding region N in sequence. 核酸组合物I结合区 ; The length of the spacer region of the nucleic acid composition I is 1-10 nt; N 核酸组合物I结合区 =N 核酸组合物I间隔区 ; The nucleic acid sequence II is divided into N 核酸组合物II结合区 Nucleic acid composition II binding region and N 核酸组合物II间隔区 The nucleic acid composition II spacer region; the nucleic acid composition II binding region and the nucleic acid composition II spacer region are alternately distributed in sequence; the N 核酸组合物II结合区 The nucleic acid composition II binding regions are numbered sequentially as nucleic acid composition II binding region 1 to nucleic acid composition II binding region N. 核酸组合物 II 结合区 ; The length of the spacer region of the nucleic acid composition II is 1-10 nt; N 核酸组合物II结合区 =N 核酸组合物II间隔区 ; N 核酸组合物I结合区 +N 核酸组合物II结合区 =N mRNA结合区 ; The nucleic acid composition I binding region 1 to the nucleic acid composition I binding region N 核酸组合物I结合区 Complementary to the odd-numbered mRNA binding regions in sequence; the nucleic acid composition II binding region 1 to the nucleic acid composition II binding region N 核酸组合物II结合区 They are complementary to the even-numbered mRNA binding regions in sequence.
2. The nucleic acid composition for mRNA delivery and expression according to claim 1, characterized in that: The nucleic acid composition I and the nucleic acid composition II are both modified with a cell-penetrating peptide.
3. The nucleic acid composition for mRNA delivery and expression according to claim 2, characterized in that: The cell-penetrating peptide is TAT.
4. The nucleic acid composition for mRNA delivery and expression according to claim 1, characterized in that The nucleic acid sequence I is circular DNA, circular RNA, single-stranded DNA or single-stranded RNA; the nucleic acid sequence II is circular DNA, circular RNA, single-stranded DNA or single-stranded RNA.
5. The nucleic acid composition for mRNA delivery and expression according to claim 1, characterized in that: The nucleotide sequence of the spacer region of the nucleic acid composition I is CCCCCC; the nucleotide sequence of the spacer region of the nucleic acid composition II is CCCCCC.
6. A method for improving mRNA delivery efficiency, characterized in that: The method comprises the steps of complementary combining the nucleic acid composition I and the nucleic acid composition II with the mRNA to form a nucleic acid composition, so as to improve the delivery efficiency of the mRNA; The mRNA is divided into N mRNA结合区 mRNA binding region and N mRNA结合区 -1 mRNA active region; the mRNA binding region and the mRNA active region are alternately distributed in sequence; the N mRNA结合区 The mRNA binding regions are numbered from binding region 1 to binding region N. mRNA结合区 ; The length L of the mRNA binding region mRNA结合区 is 5-20nt; the length L of the mRNA active region mRNA活性区 10-150 nt; The length of mRNA L mRNA =L mRNA结合区 ×N mRNA结合区 +L mRNA活性区 ×(N mRNA结合区 -1); The nucleic acid sequence I is divided into N 核酸组合物I结合区 A nucleic acid composition I binding region and N 核酸组合物I间隔区 The nucleic acid composition I spacer region; the nucleic acid composition I binding region and the nucleic acid composition I spacer region are alternately distributed in sequence; and are numbered as nucleic acid composition I binding region 1 to nucleic acid composition I binding region N in sequence. 核酸组合物I结合区 ; The length of the spacer region of the nucleic acid composition I is 1-10 nt; N 核酸组合物I结合区 =N 核酸组合物I间隔区 ; The nucleic acid sequence II is divided into N 核酸组合物II结合区 Nucleic acid composition II binding region and N 核酸组合物II间隔区 The nucleic acid composition II spacer region; the nucleic acid composition II binding region and the nucleic acid composition II spacer region are alternately distributed in sequence; the N 核酸组合物II结合区 The nucleic acid composition II binding regions are numbered sequentially as nucleic acid composition II binding region 1 to nucleic acid composition II binding region N. 核酸组合物 II 结合区 ; The length of the spacer region of the nucleic acid composition II is 1-10 nt; N 核酸组合物II结合区 =N 核酸组合物II间隔区 ; N 核酸组合物I结合区 +N 核酸组合物II结合区 =N mRNA结合区 ; The nucleic acid composition I binding region 1 to the nucleic acid composition I binding region N 核酸组合物I结合区 Complementary to the odd-numbered mRNA binding regions in sequence; the nucleic acid composition II binding region 1 to the nucleic acid composition II binding region N 核酸组合物II结合区 They are complementary to the even-numbered mRNA binding regions in sequence.
7. The method according to claim 6, characterized in that The nucleic acid composition I and the nucleic acid composition II are both modified with a cell-penetrating peptide.
8. The method according to claim 7, characterized in that The method for modifying the cell-penetrating peptide with the nucleic acid composition I comprises: performing azide modification on the nucleic acid sequence I to obtain an azide-functionalized nucleic acid composition I, and then reacting with a DBCO-modified cell-penetrating peptide to obtain a cell-penetrating peptide-modified nucleic acid composition I; The method for modifying the cell-penetrating peptide with the nucleic acid composition II comprises: performing azide modification on the nucleic acid sequence II to obtain an azide-functionalized nucleic acid composition II, and then reacting with a DBCO-modified cell-penetrating peptide to obtain a cell-penetrating peptide-modified nucleic acid composition II.
9. The method according to claim 1, characterized in that: The nucleotide sequence of the spacer region of the nucleic acid composition I is CCCCCC; the nucleotide sequence of the spacer region of the nucleic acid composition II is CCCCCC.
10. Use of the nucleic acid composition for mRNA delivery and expression according to any one of claims 1 to 5 in the preparation of mRNA drugs.
Citation Information
Patent Citations
Circular RNA (Ribonucleic Acid) molecule for tissue specific expression and application of circular RNA molecule
CN114591952A
Small interfering nucleic acid as well as preparation and application thereof
CN116410978A
RNA-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor
US20150111948A1
Folding mRNA into a nanoscale delivery vehicle
WO2023133546A2
